Oramed Pharmaceuticals Reports Results In Phase 2b Trial Of Oral Insulin Administration To Type 2 Diabetes Patients

Oramed Pharmaceuticals Inc. (OTCBB: ORMP), a developer of alternative drug delivery systems, reported results for the recently completed Phase 2b non-FDA clinical trial of its flagship oral insulin capsule, ORMD-0801. The randomized, double-blind, placebo-controlled, multi-centered study conducted in South Africa evaluated responses of 29 Type 2 diabetes patients to ORMD-0801…